• Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression.Abstract

    OBJECTIVE: To examine the associations between pharmaceutically treated anxiety and depression and incident cardiovascular disease (CVD) among 1-year prostate cancer survivors. PATIENTS AND METHODS: A registry-based cohort study design was used toescribe the risk of incident CVD in adult 1-year prostate cancer survivors without a history of CVD

    Wollersheim BM, Boekhout AH, van der Poel HG, van dePoll-Franse LV, Schoormans D. BJU Int. 2019 Nov 26;
  • Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes.Abstract

    PURPOSE: The prevalence of colorectal cancer is higher among patients with type 2 diabetes mellitus (T2D) than among patients without diabetes. Furthermore, men are at higher risk for developing colorectal cancer than women in the general populatioand also subsite-specific risks differ per sex. The aim was to evaluate the impact of T2D on these associations

    Overbeek JA, Kuiper JG, van der Heijden Aawa, Labots M, Haug U, Herings RMC, Nijpels G. Int J Colorectal Dis. 2019 Nov 12; 34 269-276.
  • Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.Abstract

    One of the more recently investigated adverse long-term side effects of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease (CVD). Studies suggest lower risk of CVD following GnRH antagonists (degareli) than GnRH agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of CVD following GnRH agonists and antagonists for PCa

    George G, Scailteux LM, Garmo H, Balusson F, Cardwell C, DeCoster G, DeSchutter H, Kuiper JG, McMenamin U, Verbeeck J, VanHemelrijck M. Fundam Clin Pharmacol. 2019 Feb 18; 33 479-499.
  • Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries.Abstract

    OBJECTIVE: To investigate whether women with type 2 diabetes (T2D) develop a more advanced stage of breast cancer and whether treatment with insulin (analogs) is associated with specific breast cancer characteristics. RESEARCH DESIGN AND METHODS: Fr this nested case-control study, women with breast cancer diagnosed in 2002-2014 were selected from the linked Netherlands Cancer Registry-PHARMO Database Network (N = 33,377)

    Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, van der Heijden Aawa, Bronsveld HK, Herings RMC, Schmidt MK, Nijpels G. Diabetes Care. 2019 Jan 24; 42 434-442.
  • Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes.Abstract

    AIM: This study explores the changes in glucose-lowering drug (GLD) use before and after cancer diagnosis among patients with diabetes. METHODS: New GLD users (1998-2011) living in the Dutch ECR-PHARMO catchment area were selected from the PHARMO Dtabase Network (n=52,228). Those with a primary cancer diagnosis were considered cases (n=3281) and matched with eligible controls (n=12,891) without cancer during follow-up

    Zander s MMJ, Haak HR, van Herk-Sukel MPP, Herings RMC, van dePoll-Franse LV, Johnson JA. Diabetes Metab. 2018 Oct 21; 44 22 - 29.
  • Risk of dipeptidyl-peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis.Abstract

    BACKGROUND: The long-term impact of DPP-4 inhibition is unknown and there are concerns about the influence of DPP-4 inhibition on carcinogenesis of the pancreas and thyroid. As DPP-4 is a rather unselective enzyme present in many tissues, we focuseon all specific cancer types. METHODS: PubMed and EMBASE were searched between Jan 2005 and Apr 2017 to identify studies comparing DPP-4 inhibitors with either placebo or active drugs on cancer risk

    Overbeek JA, Bakker M, van der Heijden Aawa, van Herk-Sukel MPP, Herings RMC, Nijpels G. Diabetes Metab Res Rev. 2018 Mar 23; 34 e3004.
  • A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study).Abstract

    Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children. Objective: The aim of this study was toompare incidence rates (IRs) of lymphoma and skin cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects

    Castellsague J, Kuiper JG, Pottegard A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Clin Epidemiol. 2018 10 299-310.
  • Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.Abstract

    Immortal time bias (ITB) is still seen frequently in medical literature. However, not much is known about this bias in the field of cancer (pharmaco-)epidemiology. In context of a hypothetical beneficial beta-blocker use among cancer patients, we amed to demonstrate the magnitude of ITB among 9876 prostate, colorectal, lung and pancreatic cancer patients diagnosed between 1998 and 2011, which were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network

    Weberpals J, Jansen L, van Herk-Sukel MPP, Kuiper JG, Aarts MJ, Vissers PAJ, Brenner H. Eur J Epidemiol. 2017 Sep 01; 1019 - 103.
  • Statin Use After Diagnosis of Colon Cancer and Patient Survival.Abstract

    BACKGROUND & AIMS: Statin use has been associated with a reduced incidence of colorectal cancer and might also affect survival of patients diagnosed with colon cancer. Statins are believed to inhibit Ras signaling and may also activate the bone morhogenetic protein (BMP) signaling pathway in colorectal cancer cells

    Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zander s MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, van deVelde CJH, Hardwick JCH, Liefers GJ. Gastroenterology. 2017 Aug; 153 470-479 e4.
  • Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors.Abstract

    PURPOSE: To examine the associations between pharmaceutically treated anxiety and depression present in the year prior to breast cancer diagnosis and the risk of incident cardiovascular disease (CVD), while controlling for traditional cardiovascularisk factors and clinical characteristics in a population-based observational study

    Schoormans D, van dePoll-Franse L, Vissers P, van Herk-Sukel MPP, Peder sen SS, Rottmann N, Horsbol T, Dalton S, Denollet J. Breast Cancer Res Treat. 2017 Jul 17; 259-266.